A new market outlook forecasts the global cell viability assays market will grow at a 6.8% compound annual growth rate to reach about US$3.8 billion by 2034. The projection covers the 2026–2034 period and evaluates market share and growth across key product types and end uses.
Rising demand from pharmaceutical research and drug discovery programs is cited as a primary growth driver, alongside expanding diagnostic and clinical applications. Advances in automated cell analysis and higher throughput workflows are also supporting broader adoption of viability assays in both research and clinical laboratory settings.
The report segments the market by product, highlighting consumables, reagents, assay kits and other consumables as core categories. Assay kits and reagent solutions remain central to routine viability testing, while consumables and automation-compatible formats are becoming more important as labs scale up testing volumes.
Looking ahead, steady CAGR expansion through 2034 is expected to create opportunities for assay manufacturers, reagent suppliers and automation vendors to capture share. Continued investment in drug discovery, diagnostics and automated cell analysis platforms will likely shape product innovation and purchasing decisions across the sector.
